Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs, Critical Reviews in Oncology/Hematology, vol.88, issue.3, pp.504-513, 2013. ,
DOI : 10.1016/j.critrevonc.2013.06.010
Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents, Nanomedicine: Nanotechnology, Biology and Medicine, vol.10, issue.1, 2014. ,
DOI : 10.1016/j.nano.2013.07.005
Determining the optimal dose in the development of anticancer agents, Nature Reviews Clinical Oncology, vol.30, issue.5, pp.272-281, 2014. ,
DOI : 10.1634/theoncologist.12-8-913
The big picture on small medicine: the state of nanomedicine products approved for use in clinical trials, Nanomedicine Nanotechnol Biol Med. 2013, vol.9, issue.1, pp.1-14 ,
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology, Pharmaceutics, vol.10, issue.1, pp.137-174, 2014. ,
DOI : 10.1016/S0074-7696(08)62148-8
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents, Clinical Cancer Research, vol.11, issue.23, pp.8230-8234, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-1895
URL : http://clincancerres.aacrjournals.org/content/clincanres/11/23/8230.full.pdf
Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times, JNCI Journal of the National Cancer Institute, vol.81, issue.19, pp.1484-1488, 1989. ,
DOI : 10.1093/jnci/81.19.1484
Pharmacokinetics of stealth versus conventional liposomes: effect of dose, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1068, issue.2, pp.133-141, 1991. ,
DOI : 10.1016/0005-2736(91)90201-I
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting, Advances in Enzyme Regulation, vol.41, issue.1, pp.189-207, 2001. ,
DOI : 10.1016/S0065-2571(00)00013-3
Challenges in Development of Targeted Liposomal Therapeutics, The AAPS Journal, vol.14, issue.2, pp.303-315, 2012. ,
DOI : 10.1208/s12248-012-9330-0
URL : http://europepmc.org/articles/pmc3326155?pdf=render
Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?, Theranostics, vol.4, issue.1, pp.81-89, 2013. ,
DOI : 10.7150/thno.7193
URL : http://www.thno.org/v04p0081.pdf
Image-guided and passively tumourtargeted polymeric nanomedicines for radiochemotherapy, Br J Cancer, vol.99, 2008. ,
DOI : 10.1038/sj.bjc.6604561
URL : http://www.nature.com/bjc/journal/v99/n6/pdf/6604561a.pdf
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?, Bioconjugate Chemistry, vol.27, issue.10, 2016. ,
DOI : 10.1021/acs.bioconjchem.6b00437
Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice, Molecular Pharmaceutics, vol.10, issue.5, pp.2031-2044, 2013. ,
DOI : 10.1021/mp400054e
URL : http://europepmc.org/articles/pmc3651790?pdf=render
Current trends in the use of liposomes for tumor targeting, Nanomedicine, vol.25, issue.9, 2013. ,
DOI : 10.1517/17425247.2010.538678
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors, Journal of Controlled Release, vol.150, issue.1, pp.117-124, 2011. ,
DOI : 10.1016/j.jconrel.2010.11.006
Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel, Clinical Cancer Research, vol.12, issue.4, pp.1317-1324, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-1634
URL : http://clincancerres.aacrjournals.org/content/clincanres/12/4/1317.full.pdf
Folate-targeted docetaxel-lipid-basednanosuspensions for active-targeted cancer therapy, Int J Nanomedicine, vol.7, pp.3281-3294, 2012. ,
The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs, Advanced Drug Delivery Reviews, vol.40, issue.1-2, pp.75-87, 1999. ,
DOI : 10.1016/S0169-409X(99)00041-1
Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1104, issue.1, pp.95-101, 1992. ,
DOI : 10.1016/0005-2736(92)90136-A
Renal clearance of quantum dots, Nature Biotechnology, vol.361, issue.10, pp.1165-1170, 1340. ,
DOI : 10.1152/ajprenal.00316.2002
Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters, Pharmaceutical Research, vol.88, issue.3, pp.2677-2684, 2014. ,
DOI : 10.1016/j.critrevonc.2013.06.010
URL : https://hal.archives-ouvertes.fr/hal-01773009
Rate of biodistribution of STEALTH?? liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1609, issue.1, pp.102-108, 2003. ,
DOI : 10.1016/S0005-2736(02)00661-2
Influence of Vesicle Size, Lipid Composition, and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin in Mice, Cancer Res, vol.49, pp.5922-5930, 1989. ,
Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components, Life Sciences, vol.30, issue.24, pp.2123-2136, 1982. ,
DOI : 10.1016/0024-3205(82)90455-6
Influence of cholesterol on liposome stability and on in vitro drug release, Drug Delivery and Translational Research, vol.135, issue.3, pp.231-242, 2015. ,
DOI : 10.1063/1.3615937
Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina, Nanotechnology, vol.25, issue.27, pp.957-4484, 2014. ,
DOI : 10.1088/0957-4484/25/27/275103
The role of surface charge and hydrophilic groups on liposome clearance in vivo, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1103, issue.1, pp.94-100, 1992. ,
DOI : 10.1016/0005-2736(92)90061-P
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating, International Journal of Pharmaceutics, vol.240, issue.1-2, pp.95-102, 2002. ,
DOI : 10.1016/S0378-5173(02)00129-1
The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate, Int J Nanomedicine, vol.11, pp.4187-4197, 2016. ,
Cationic Charge Determines the Distribution of Liposomes between the Vascular and Extravascular Compartments of Tumors, Cancer Res, vol.62, pp.6831-6836, 2002. ,
Relationships between Liposome Properties, Cell Membrane Binding, Intracellular Processing, and Intracellular Bioavailability, The AAPS Journal, vol.13, issue.4, pp.585-597, 2011. ,
DOI : 10.1208/s12248-011-9298-1
The importance of nanoparticle shape in cancer drug delivery, Expert Opinion on Drug Delivery, vol.4, issue.2, pp.129-142, 2014. ,
DOI : 10.1021/ar300015b
journey of nanoparticles, Nanomedicine, vol.2535, issue.1, pp.121-134, 2014. ,
DOI : 10.1021/nl073154m
Role of target geometry in phagocytosis, Proceedings of the National Academy of Sciences, vol.298, issue.2, pp.4930-4934, 2006. ,
DOI : 10.1016/j.ijpharm.2005.03.035
Particle shape enhances specificity of antibody-displaying nanoparticles, Proceedings of the National Academy of Sciences, vol.110, issue.9, pp.3270-3275, 2013. ,
DOI : 10.1073/pnas.0705326104
Personalized liposome???protein corona in the blood of breast, gastric and pancreatic cancer patients, The International Journal of Biochemistry & Cell Biology, vol.75, pp.180-187, 2016. ,
DOI : 10.1016/j.biocel.2015.09.002
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nature Nanotechnology, vol.100, issue.2, pp.137-143, 2013. ,
DOI : 10.1073/pnas.2232479100
Effects of the protein corona on liposome?liposome and liposome?cell interactions, Int J Nanomedicine, vol.11, pp.3049-3063, 2016. ,
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1663, issue.1-2, pp.167-177, 2004. ,
DOI : 10.1016/j.bbamem.2004.03.006
Rapid Method for Determination of Residual tert-Butanol in Liposomes Using Solid-Phase Microextraction and Gas Chromatography, Journal of Chromatographic Science, vol.48, issue.4, pp.289-293, 2010. ,
DOI : 10.1093/chromsci/48.4.289
Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis, Journal of Chromatography A, vol.979, issue.1-2, pp.379-388, 2002. ,
DOI : 10.1016/S0021-9673(02)01440-1
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma, Cancer Chemotherapy and Pharmacology, vol.53, issue.4, pp.329-336, 2003. ,
DOI : 10.1007/s00280-003-0719-4
Profiling the relationship between tumorassociated macrophages and pharmacokinetics of liposomal agents in preclinical murine models, Nanomedicine Nanotechnol Biol Med ,
Oxygen microenvironment affects the uptake of nanoparticles in head and neck tumor cells, Energy-based Treatment of Tissue and Assessment VII, p.10, 1117. ,
DOI : 10.1117/12.2008067
Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer., Journal of Clinical Oncology, vol.34, issue.4_suppl, pp.439-439, 2016. ,
DOI : 10.1200/jco.2016.34.4_suppl.439
Nanomedicine applied to translational oncology: A future perspective on cancer treatment, Nanomedicine: Nanotechnology, Biology and Medicine, vol.12, issue.1, pp.81-103, 2016. ,
DOI : 10.1016/j.nano.2015.08.006
Factors affecting drug release from liposomes, Curr Opin Drug Discov Devel, vol.13, pp.111-123, 2010. ,
Innate immunity in aging: impact on macrophage function, Aging Cell, vol.47, issue.4, pp.161-167, 2004. ,
DOI : 10.1126/science.1094351
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70??years old, Cancer Chemotherapy and Pharmacology, vol.105, issue.1, pp.517-524, 2014. ,
DOI : 10.1016/j.jconrel.2005.04.003
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors, International Journal of Nanomedicine, vol.10, pp.1201-1209, 2015. ,
DOI : 10.2147/IJN.S62911
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients, Cancer Chemotherapy and Pharmacology, vol.66, issue.4, pp.43-50, 2011. ,
DOI : 10.1007/s00280-010-1406-x
Gender Effects in Pharmacokinetics and Pharmacodynamics, Drugs, vol.50, issue.2, pp.222-239, 1995. ,
DOI : 10.2165/00003495-199550020-00003
The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.13003, 2010. ,
DOI : 10.1200/jco.2010.28.15_suppl.e13003
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel, Cancer Chemotherapy and Pharmacology, vol.53, issue.5, pp.452-457, 2004. ,
DOI : 10.1007/s00280-003-0750-5
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents, Nanomedicine, vol.27, issue.10, pp.447-463, 2015. ,
DOI : 10.1007/s00280-007-0525-5
Nanoparticles and the Mononuclear Phagocyte System: Pharmacokinetics and Applications for Inflammatory Diseases, Current Rheumatology Reviews, vol.10, issue.1, pp.22-34, 2014. ,
DOI : 10.2174/1573403X10666140914160554
Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance, ACS Nano, vol.10, issue.1, pp.861-870, 2016. ,
DOI : 10.1021/acsnano.5b05999
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells, Immunological Reviews, vol.176, issue.1, pp.162-179, 2008. ,
DOI : 10.4049/jimmunol.176.11.6752
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors, Journal of Liposome Research, vol.13, issue.2, pp.158-165, 2010. ,
DOI : 10.1158/1078-0432.CCR-07-1035
Genotype of Patients With Cancer, Journal of Clinical Oncology, vol.32, issue.22, pp.2328-2334, 2014. ,
DOI : 10.1200/JCO.2014.55.2307
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.25, issue.4, pp.699-705, 2012. ,
DOI : 10.1634/theoncologist.2007-0180
Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response, Journal of Clinical Oncology, vol.23, issue.16_suppl, pp.2017-2017, 2005. ,
DOI : 10.1200/jco.2005.23.16_suppl.2017
In Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity, Pharmaceutical Research, vol.58, issue.13, pp.1281-1290, 2013. ,
DOI : 10.1200/JCO.1998.16.1.301
Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains, Nanomedicine: Nanotechnology, Biology and Medicine, vol.12, issue.7, 2007. ,
DOI : 10.1016/j.nano.2016.05.019
Fractal Characteristics of Tumor Vascular Architecture During Tumor Growth and Regression, Microcirc N Y N, pp.395-402, 1994. ,
DOI : 10.3109/10739689709146803
Transport of molecules in the tumor interstitium: a review, Cancer Res, vol.47, pp.3039-3051, 1987. ,
Computational Modeling of Nanoparticle Targeted Drug Delivery, Reviews in Nanoscience and Nanotechnology, vol.1, issue.1, pp.66-83, 2012. ,
DOI : 10.1166/rnn.2012.1014
An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity, Nanomedicine, vol.5, issue.10, pp.197-216, 2016. ,
DOI : 10.1002/smll.201401943
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy, Science, vol.307, issue.5706, pp.58-62, 2005. ,
DOI : 10.1126/science.1104819
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner, Nature Nanotechnology, vol.46, issue.6, pp.383-388, 2012. ,
DOI : 10.1083/jcb.200910104
Dissecting cancer through mathematics: from the cell to the animal model, Nature Reviews Cancer, vol.85, issue.3, pp.221-230, 2010. ,
DOI : 10.1016/j.ijrobp.2003.09.035
Continuous and Discrete Mathematical Models of Tumor-induced Angiogenesis, Bulletin of Mathematical Biology, vol.60, issue.5, pp.857-899, 1998. ,
DOI : 10.1006/bulm.1998.0042
How tumour-induced vascular changes alter angiogenesis: Insights from a computational model, Journal of Theoretical Biology, vol.419, pp.211-226, 2017. ,
DOI : 10.1016/j.jtbi.2017.02.018
Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method, Bulletin of Mathematical Biology, vol.67, issue.2, pp.211-259, 2005. ,
DOI : 10.1016/j.bulm.2004.08.001
Two-Dimensional Chemotherapy Simulations Demonstrate Fundamental Transport and Tumor Response Limitations Involving Nanoparticles, Biomedical Microdevices, vol.6, issue.4, pp.297-309, 2004. ,
DOI : 10.1023/B:BMMD.0000048562.29657.64
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors, AIP Advances, vol.5, issue.7, 2012. ,
DOI : 10.1063/1.3699060.1
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors, European Journal of Clinical Pharmacology, vol.6, issue.9, 2013. ,
DOI : 10.1007/s00280-005-0166-5
, Eur J Clin Pharmacol, vol.69, pp.2073-2081
Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies, The Journal of Clinical Pharmacology, vol.25, issue.6, pp.180-194, 2012. ,
DOI : 10.1007/s10585-008-9191-1
Allometric scaling of pegylated liposomal anticancer drugs, Journal of Pharmacokinetics and Pharmacodynamics, vol.4, issue.11, p.653, 2011. ,
DOI : 10.1038/clpt.2009.141
Physiologically Based Pharmacokinetic Modeling of Nanoparticles, ACS Nano, vol.4, issue.11, pp.6303-6317, 2010. ,
DOI : 10.1021/nn1018818
A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice, Nanotoxicology, vol.46, pp.162-172, 2016. ,
DOI : 10.1093/toxsci/kfp087
A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles, Nanomedicine, vol.11, issue.2, 2016. ,
DOI : 10.1038/nnano.2015.111
Evaluation of Nanoparticle Uptake in Co-culture Cancer Models, PLoS ONE, vol.277, issue.7, 2013. ,
DOI : 10.1371/journal.pone.0070072.s005
Cancer cell spheroids as a model to evaluate chemotherapy protocols, Cancer Biology & Therapy, vol.11, issue.12, pp.1205-1213, 2012. ,
DOI : 10.1158/1535-7163.MCT-06-0698
URL : https://hal.archives-ouvertes.fr/hal-02130815
An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids, Scientific Reports, vol.1, issue.1, 2015. ,
DOI : 10.1038/nprot.2006.339
Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors, The Oncologist, vol.17, issue.10, pp.1303-1316, 2012. ,
DOI : 10.1634/theoncologist.2012-0274